SCHEMBL3859847

SCHEMBL3859847

C1CN2CC[C]2CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4977848 0.86 HTR2C (0.39)
SCHEMBL338532 0.83 HTR2C (0.49)
SCHEMBL368445 0.81 HTR2C (0.47)
SCHEMBL28620324 0.75
SCHEMBL18692327 0.74
SCHEMBL1481868 0.70 ALDH1A1 (0.46)
SCHEMBL28691107 0.68 USP2 (0.48)
SCHEMBL1481847 0.68 USP2 (0.48)
SCHEMBL18692533 0.67
SCHEMBL18285512 0.62 SLC6A2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193168-B2 Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release REDPOINT BIO CORPORATION (US) 2012-06-05 US disclosed
EP-2107908-A2 USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE Redpoint Bio Corporation (US) 2009-10-14 EP disclosed
EP-1951215-A4 HYDRAZONE DERIVATIVES AND USES THEREOF REDPOINT BIO CORP (US) 2009-07-29 EP disclosed
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release REDPOINT BIO CORPORATION (US) 2008-12-11 US disclosed
WO-2008097504-A2 USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE REDPOINT BIO CORPORATION (US) 2008-08-14 WO disclosed
EP-1951215-A2 HYDRAZONE DERIVATIVES AND USES THEREOF Redpoint Bio Corporation (US) 2008-08-06 EP disclosed
US-20070207093-A1 Hydrazone derivatives and uses thereof LINQUAGEN CORP. 2007-09-06 US disclosed
WO-2007056159-A2 HYDRAZONE DERIVATIVES AND USES THEREOF REDPOINT BIO CORPORATION (US) 2007-05-18 WO disclosed